ArticleJournal of immunology (Baltimore, Md. : 1950)2018
Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development.
Open access · bronzeAbstract read
In one paragraph
Article in Journal of immunology (Baltimore, Md. : 1950), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 19% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Proteomics in Patients with Fibromyalgia Syndrome: A Systematic Review of Observational Studies.Current pain and headache reports · 2024Pooled it
- Trial
- Radiotherapy Reprograms Intermediate Monocytes Into Proinflammatory Drivers of Systemic Inflammation in Radiation-Induced Heart Disease.Cardiology research and practice · 2026Article
- Differential associations between relationship stressors and natural killer cell gene expression by race/ethnicity and sex among older U.S. adults.Brain, behavior, and immunity · 2025Article
- Immune landscape in children with X-linked retinoschisis.BMC immunology · 2025Article
- A Comprehensive Review of Fc Gamma Receptors and Their Role in Systemic Lupus Erythematosus.International journal of molecular sciences · 2025Review
- NK Cytotoxicity Mediated by NK-92 Cell Lines Expressing Combinations of Two Allelic Variants forAntibodies (Basel, Switzerland) · 2024Article
- Increased CD16a (FcγRIIIA) Expression in The Tumor Microenvironment of Atypical Neurofibromatous Neoplasms of Uncertain Biologic Potential May Be Associated with Progression from Neurofibromas to Atypical Neurofibromas.Journal of personalized medicine · 2023Article
- Effects of epigenetic therapy on natural killer cell function and development in hematologic malignancy.Journal of leukocyte biology · 2023Review
- Viral- and tumor-reactive natural killer cells.Seminars in immunology · 2023Review
- Multiscale Methods for Signal Selection in Single-Cell Data.Entropy (Basel, Switzerland) · 2022Article
- Heterogeneity in IgG-CD16 signaling in infectious disease outcomes.Immunological reviews · 2022Review
- Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma.Blood cancer discovery · 2022Article
- Capturing 3D Chromatin Maps of Human Primary Monocytes: Insights From High-Resolution Hi-C.Frontiers in immunology · 2022Article
- Article
- SIV-induced terminally differentiated adaptive NK cells in lymph nodes associated with enhanced MHC-E restricted activity.Nature communications · 2021Article
- Comprehensive mapping of immune perturbations associated with severe COVID-19.Science immunology · 2020Article
- Exosome-derived uterine miR-218 isolated from cows with endometritis regulates the release of cytokines and chemokines.Microbial biotechnology · 2020Article
- Recent Advances in Molecular Mechanisms of the NKG2D Pathway in Hepatocellular Carcinoma.Biomolecules · 2020Review
- Macrophages protect mycoplasma-infected chronic myeloid leukemia cells from natural killer cell killing.Immunology and cell biology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Aaron R VictorMedical Scientist Training Program, The Ohio State University, Columbus, OH 43210.ORCID 0000-0003-4118-3088
Christoph WeigelThe Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH 43210.
Steven D ScovilleMedical Scientist Training Program, The Ohio State University, Columbus, OH 43210.
Wing Keung ChanThe Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH 43210.ORCID 0000-0002-5257-1521
Kelsey ChatmanCollege of Medicine, The Ohio State University, Columbus, OH 43210.ORCID 0000-0001-9490-0058
Mary M NemerCollege of Medicine, The Ohio State University, Columbus, OH 43210.
Charlene MaoThe Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH 43210.ORCID 0000-0002-5517-7183
Karen A YoungThe Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH 43210.
Jianying ZhangCenter for Biostatistics, Department of Bioinformatics, The Ohio State University, Columbus, OH 43210.
Jianhua YuThe Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH 43210.
Aharon G FreudDepartment of Pathology, The Ohio State University, Columbus, OH 43210.
Christopher C OakesThe Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH 43210; Michael.Caligiuri@osumc.edu Christopher.Oakes@osumc.edu.
Michael A CaligiuriThe Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH 43210; Michael.Caligiuri@osumc.edu Christopher.Oakes@osumc.edu.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · USThe Ohio State University · US
Funding
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3MTWO SIGNAL REQUIREMENT FOR NATURAL KILLER IMMUNITYP01CA095426 · NCI · OHIO STATE UNIVERSITY · PI CALIGIURI, MICHAEL A · 2002 to 2016
$29.6MThe Tumor Microenvironmental Barrier to Effective Viral OncolysisP01CA163205 · NCI · OHIO STATE UNIVERSITY · PI MICHAEL A CALIGIURI · 2013 to 2026
$26.0MONOCOLOGY TRAINING GRANTT32CA009338 · NCI · OHIO STATE UNIVERSITY · PI BYRD, JOHN C., POLLOCK, RAPHAEL E. · 1985 to 2018
$8.3MHuman natural killer cells: Advancing biology and clinical applicationsR35CA210087 · NCI · OHIO STATE UNIVERSITY · PI MICHAEL A CALIGIURI · 2017 to 2026
$8.3MIL-15--CHARACTERIZATION THROUGH EXPERIMENTAL IMMUNOLOGYR01CA068458 · NCI · ROSWELL PARK CANCER INSTITUTE · PI CALIGIURI, MICHAEL A, YU, JIANHUA · 1996 to 2019
$4.5MElucidation of Human Natural Killer Cell DevelopmentR01CA208353 · NCI · OHIO STATE UNIVERSITY · PI AHARON G FREUD · 2017 to 2026
$4.0MElucidate and Modulate Cell Signaling in NK Cells for Glioma TreatmentR01AI129582 · NIAID · OHIO STATE UNIVERSITY · PI YU, JIANHUA · 2017 to 2021
$2.1MOvercoming Barriers of Virotherapy by Next-Generation oHSV Expressing E-CadherinR01NS106170 · NINDS · OHIO STATE UNIVERSITY · PI YU, JIANHUA · 2018 to 2023
$1.9MEnhancing NK Cell Activity by Dietary Diphyllin Lignans for Cancer PreventionR01CA185301 · NCI · OHIO STATE UNIVERSITY · PI CALIGIURI, MICHAEL A, YU, JIANHUA · 2015 to 2019
$1.8MIL-15 characterization through experimental immunologyR37CA068458 · NCI · OHIO STATE UNIVERSITY · PI CALIGIURI, MICHAEL A · 2010 to 2014
$1.4MNCI NIH HHS L30 CA199447NCI NIH HHS P01 CA095426NCI NIH HHS P01 CA163205NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA068458NCI NIH HHS R01 CA185301NCI NIH HHS R01 CA208353NCI NIH HHS R35 CA210087NCI NIH HHS R37 CA068458NCI NIH HHS T32 CA009338NIAID NIH HHS R01 AI129582NINDS NIH HHS R01 NS106170
Abstract
The surface receptor FcγRIIIA (CD16a) is encoded by the
Indexed as
Epigenesis, GeneticGene Expression Regulation, DevelopmentalRNA Processing, Post-TranscriptionalCell DifferentiationCell LineCpG IslandsDNA MethylationFlow CytometryGene SilencingGenes, ReporterGPI-Linked ProteinsHumansKiller Cells, NaturalMicroRNAsPromoter Regions, GeneticReceptors, IgGFCGR3A protein, humanFCGR3B protein, humanGPI-Linked ProteinsMicroRNAsMIRN218 microRNA, humanReceptors, IgG
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.